Compass Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-13.1M | $-10.8M | $-13.4M | $-10.0M | $-11.3M | $-7.8M | $-11.6M | $-12.0M |
| Depreciation & Amortization | $152.0K | $154.0K | $161.0K | $164.0K | $180.0K | $194.0K | $195.0K | $202.0K |
| Depreciation | $100.0K | $200.0K | $200.0K | $100.0K | $200.0K | $200.0K | $200.0K | $200.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $2.1M | $2.0M | $1.6M | $1.6M | $1.6M | $1.3M | $1.0M | $1.3M |
| Net Cash from Operating Activities | $-10.8M | $-13.9M | $-12.4M | $-5.9M | $-10.1M | $-12.2M | $-10.6M | $-10.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $0 | $9.0K | $10.0K | $11.0K | $0 | $54.0K | $27.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $6.5M | $-4.1M | $6.3M | $17.0M | $-667.0K | $4.3M | $-46.6M | $1.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.0K | $17.4M | $-158.0K | $21.0K | $3.0M | $41.0K | $75.8M | $5.0K |
| Net Change in Cash | $-4.3M | $-554.0K | $-6.2M | $11.1M | $-7.7M | $-7.9M | $18.5M | $-9.8M |
| Free Cash Flow | $-10.8M | $-13.9M | $-12.4M | $-5.9M | $-10.1M | $-12.2M | $-10.7M | $-11.0M |